Introduction
============

Understanding heterogeneous genetic alterations in tumors is recognized as a key factor in advancing cancer therapy ([@b1-ijo-48-01-0367]--[@b3-ijo-48-01-0367]). Lung cancers are classified into two subtypes, non-small cell lung carcinoma (NSCLC) and small cell lung carcinoma (SCLC), which harbor exclusive specific mutations: *RB1* in SCLC and *CDKN2A* (p16*^INK4A^*) in NSCLC ([@b4-ijo-48-01-0367]). Both the *RB1* and *CDKN2A* genes are tightly associated with cell cycle regulation, and *CDKN2A* regulates RB1 phosphorylation through cyclin E and D1 ([@b5-ijo-48-01-0367],[@b6-ijo-48-01-0367]). The crucial role of RB1 as a regulator in cell cycle progression has been intensively investigated ([@b7-ijo-48-01-0367]--[@b9-ijo-48-01-0367]). Accumulated data have demonstrated mutually exclusive mutation patterns for genes encoding proteins that function in the same biological pathway. For instance, mutations of the *KRAS* or *BRAF* gene, which are downstream of the EGFR signaling pathway, have not been found in *EGFR*-mutated NSCLC ([@b10-ijo-48-01-0367],[@b11-ijo-48-01-0367]), and co-mutations of the *TP53* and *PIK3CA* pair ([@b12-ijo-48-01-0367]) or the *RB1* and *CDKN2A* pair ([@b13-ijo-48-01-0367]) rarely occur in the same tumors. However, the biological meaning of such mutually exclusive mutation patterns is not fully understood, even though this exclusiveness does serve as an attractive target for the development of novel therapeutics ([@b14-ijo-48-01-0367]).

An understanding of differential regulation along with distinct mutations in *RB1* and *CDKN2A* is required to identify molecular characteristics of the progression of SCLC and NSCLC subtypes. Large-scale cell line-based high-throughput transcriptome and proteome datasets facilitate the understanding of molecular characterization of cancers through genome-wide functional analyses. The National Cancer Institute (NCI) released well-annotated sets of both DNA microarray data to detect the gene expression and reverse-phase protein array (RPPA) data to detect the total protein and phosphorylation on 60 well-characterized cancer cell lines ([@b15-ijo-48-01-0367]). Diverse omics datasets on an expanded panel of \>300 cancer cell lines were also generated by GlaxoSmithKline (GSK) ([@b16-ijo-48-01-0367]). Together with these datasets, the extensive mutation profile on individual cell lines is available from the COSMIC (Catalogue of Somatic Mutations in Cancer) database ([@b17-ijo-48-01-0367]). Through mutation-oriented association studies on cell line-based omics data, we have reported new targets and mechanisms for cancer regulation ([@b3-ijo-48-01-0367],[@b18-ijo-48-01-0367],[@b19-ijo-48-01-0367]).

In the present study, the regulation of gene and protein levels driven by *RB1* or *CDKN2A* mutations in lung cancer was analyzed using transcriptome and proteome datasets obtained from 318 diverse cancer cell lines. We attempted to identify the differentially regulated gene/protein signatures and functional pathways specific to *RB1* and *CDKN2A* mutations. Furthermore, we experimentally investigated whether double or complementary knockdown of *RB1* or *CDKN2A* gene expression has a specific effect on the reciprocal mutant subtype in lung cancer cell lines. We expect that this study will provide a useful resource for the regulation of lung cancer progression using synergistic mechanisms of exclusive *RB1* or *CDKN2A* mutations.

Materials and methods
=====================

Data acquisition
----------------

The large-scale transcriptome dataset on 318 cancer cell lines was obtained from the Cancer Biomedical Informatics Grid (caBIG) website (<https://cabig.nci.nih.gov/caArray_GSKdata>) ([@b16-ijo-48-01-0367]). This dataset, also known as the GlaxoSmithKline (GSK) dataset, has 950 arrays performed in triplicate for each cell line with the Affymetrix U133 Plus 2.0 Array chip. It was normalized to MAS5 and then transformed to a log2 scale.

The reverse-phase protein array (RPPA) dataset to detect protein expression and phosphorylation was generated in the Functional Proteomics Core of the M.D. Anderson Cancer Center using a total of 179 cancer cell lines, which were included in the transcriptome dataset. These cell lines were purchased from several vendors (American Type Culture Collection; Developmental Therapeutics Program, National Cancer Institute; German Resource Centre for Biological Material and European Collection of Animal Cell Cultures) and grown in standard culture media as recommended by the vendor. The genetic identity of cell lines was determined by cross comparing all cell lines in this set ([@b16-ijo-48-01-0367],[@b20-ijo-48-01-0367]). The cells were maintained in RPMI-1640 supplemented with 5% fetal bovine serum at 37°C in a humidified 5% CO~2~ atmosphere. Proteins were harvested when the cells reached \~70% confluence. The cells were lysed in buffer containing 1% Triton X-100, 50 mM HEPES pH 7.4, 150 mM NaCl, 1.5 mM MgCl~2~, 1 mM ethylene glycol tetraacetic acid, 100 mM NaF, 10 mM NaPPi, 10% glycerol, 1 mM Na~3~VO~4~ and complete protease inhibitor cocktail (Roche Diagnostics). Protein supernatants were isolated using standard methods ([@b21-ijo-48-01-0367]), and the protein concentration was determined using the bicinchoninic acid assay ([@b22-ijo-48-01-0367]). Samples were diluted to a uniform protein concentration and denatured in 1% sodium dodecyl sulfate for 10 min at 95°C. Samples were stored at −80°C until use. RPPA analysis was performed as described previously ([@b21-ijo-48-01-0367],[@b23-ijo-48-01-0367],[@b24-ijo-48-01-0367]). A logarithmic value reflecting the relative amount of each protein in each sample was generated for subsequent analyses. The RPPA analysis was performed using a total of 115 antibodies.

The annotation of somatic mutation on all cell lines was organized by the COSMIIC (Catalogue of Somatic Mutations in Cancer) database (<http://cancer.sanger.ac.uk/cosmic>) ([@b17-ijo-48-01-0367]).

Enrichment analysis of somatic mutations
----------------------------------------

To describe the selectivity of mutation occurrence, we calculated enrichment scores using an odds ratio between the observed odds and expected odds. The observed odds score is the ratio for the number of mutated cell lines in a specific cancer type via the number of cell lines in a specific cancer type. The expected odds score is the ratio for the number of mutated cell lines vs. the total number of cell lines. In addition, the probability of an odds ratio was calculated by the Fisher exact test using the R open-source computing language, version 2.15. The Fisher exact test uses a hypergeometric distribution to determine the significance of the agreement between individual question pairs ([@b25-ijo-48-01-0367]).

Mutation-specific gene and protein expression analysis
------------------------------------------------------

For the selection of *RB1* and *CDKN2A* mutation-specific gene and protein expression markers together with excluding the subtype-dependent expressions, lung cancer cell lines were classified into two groups: NSCLC and SCLC. Then, we divided the cell lines of each subtype into two groups based on the mutational status of *RB1* and *CDKN2A*. *CDKN2A*-mutant and wild-type cell lines were mainly considered in the NSCLC type. *RB1*-mutant and wild-type cell lines were considered in the SCLC type. As a result, in the transcriptome dataset, we classified 9, 16, 22 and 24 cell line samples into the following four groups, respectively: RB1*wt* SCLC; RB1*mt* SCLC; CDKN2A*wt* NSCLC; and CDKN2A*mt* NSCLC. In the RPPA dataset, we classified 4, 7, 4 and 16 cell line samples into four groups, respectively: RB1*wt* SCLC; RB1*mt* SCLC; CDKN2A*wt* NSCLC; and CDKN2A*mt* NSCLC. The gene expression was detected using a log~2~ fold change value for the average difference of mutant and wild-type cell lines. The significance was confirmed by a t-test.

The patterns of gene expression were analyzed through a hierarchical clustering method. The clustering and its visualization on a heatmap were performed using the software QCanvas ([@b26-ijo-48-01-0367]). QCanvas can be downloaded freely from the website <http://compbio.sookmyung.ac.kr/~qcanvas>.

Gene set enrichment analysis
----------------------------

Pathway analysis was performed using the GSEA (Gene Set Enrichment Analysis) method ([@b27-ijo-48-01-0367]). Gene sets, integrated from Reactome, PID, KEGG, and Biocarta database, were obtained from the online pathway database, MSigDB v3.1 (<http://www.broadinstitute.org/gsea/msigdb>). The significantly (p\<0.01) enriched gene sets among the results of the GSEA were reorganized based on major functional categories in each database.

Cell culture
------------

NCI-60 lung cancer cell lines (NCI-H460, A549, NCI-H322M, NCI-H226, EKVX, and NCI-H23) were obtained from National Cancer Institute (NCI DTP), USA. NCI-H1993, NCI-H1935, NCI-H82 and NCI-H524 were obtained from American Type Culture Collection (ATCC). All cells were grown in RPMI-1640 medium (HyClone, USA) with 10% FBS (HyClone) and 1% penicillin/streptomycin (Gibco, USA), and maintained at 37°C in a humidified atmosphere at 5% CO~2~

siRNA transfection and cell viability assay
-------------------------------------------

To detect cell viability after siRNA transfection, the cells were seeded in a 96-well plate at a density of 5,000 cells per well. After adhering for 24 h, target siRNAs were added in transfection medium (Gibco) for 6 h at 37°C in a CO~2~ incubator. siRB1 (L-003296-02), siCDKN2A (L-011007-00) and non-targeting siRNA (D-001810-10) were purchased from Dharmacon Inc. (Lafayette, CO, USA). After being cultured for 72 h at 37°C, 5% CO~2~, cell viability was detected using a CellTiter-Blue Cell Viability Assay (Promega, Madison, WI, USA).

Results and Discussion
======================

RB1 and CDKN2A mutations in SCLC and NSCLC cell lines
-----------------------------------------------------

Genetic alterations affecting the same biological pathway are generally not found in the same cancer cell. Accordingly, exclusive mutation patterns of *RB1* and *CDKN2A* genes have been observed in the lung cancer subtypes SCLC and NSCLC ([@b4-ijo-48-01-0367],[@b13-ijo-48-01-0367]). Based on the analysis of mutation frequencies across 318 cell lines, we found the general exclusiveness of *RB1* and *CDKN2A* mutations in diverse cancer lineages ([Fig. 1A](#f1-ijo-48-01-0367){ref-type="fig"}). *RB1* mutations were significantly enriched in urinary tract and lung cancer cell lines yet rarely found in liver, renal, pancreatic and skin cancers, in which *CDKN2A* mutations were frequent. Furthermore, among 71 lung cancer cell lines, 25 SCLC-derived cells were significantly enriched with *RB1* mutations, whereas 46 NSCLCs predominantly contained *STK11, KRAS* and *CDKN2A* mutations ([Fig. 1B](#f1-ijo-48-01-0367){ref-type="fig"}). Taken together, the mutations of *RB1* and *CDKN2A* genes, which belong to a common functional pathway, were clearly exclusive from each other among frequently mutated genes in diverse cancer cell lines ([Fig. 1C](#f1-ijo-48-01-0367){ref-type="fig"}).

Differential gene expression profiles between RB1mt SCLCs and CDKN2Amt NSCLCs
-----------------------------------------------------------------------------

To find lineage-independent, mutation-specific gene expression patterns, we classified 9, 16, 22 and 24 cell line samples into four groups, RB1*wt* SCLC, RB1*mt* SCLC, CDKN2A*wt* NSCLC and CDKN2A*mt* NSCLC, and analyzed the group-specific gene expression patterns using DNA microarray data. There was no general correlation of gene expression between the SCLC and NSCLC cell lines ([Fig. 2A](#f2-ijo-48-01-0367){ref-type="fig"}), and significantly enriched gene sets were also different between the lung subtypes. However, RB1*mt* SCLC and CDKN2A*mt* NSCLC cells showed a negative correlation in gene expression ([Fig. 2B](#f2-ijo-48-01-0367){ref-type="fig"}), whereas RB1*wt* SCLC and CDKN2A*wt* NSCLC exhibited a positive correlation ([Fig. 2C](#f2-ijo-48-01-0367){ref-type="fig"}). This observation indicated that *RB1* and *CDKN2A* mutations caused lineage-specific distinctive changes in gene expression.

Our analysis showed that the lineage difference was generally more important than *RB1* and *CDKN2A* mutational status in the differential gene expression pattern ([Fig. 3A](#f3-ijo-48-01-0367){ref-type="fig"}). Thus, we attempted to identify RB1*mt*- and CDKN2A*mt*-specific gene signatures by separately analyzing SCLC and NSCLC cells ([Fig. 3B](#f3-ijo-48-01-0367){ref-type="fig"}). As a result, we were able to identify distinct mutation-specific gene signatures for which expression was significantly regulated (\>2-fold change and p\<0.05) in each subtype ([Tables I](#tI-ijo-48-01-0367){ref-type="table"} and [II](#tII-ijo-48-01-0367){ref-type="table"}). Of note, the significantly over-enriched (p\<0.01) gene sets (functional categories of selected gene signatures) generally did not overlap between the two mutation groups ([Fig. 3B](#f3-ijo-48-01-0367){ref-type="fig"}). The upregulated gene sets with *RB1* mutation in SCLC cell lines mainly belonged to functional categories of transcription. The hit list included known target genes of E2F, which are released and activated upon *RB1* inactivation ([@b28-ijo-48-01-0367]). The upregulated genes upon *CDKN2A* mutation in NSCLC cell lines were largely enriched in the gene sets of extracellular matrix and metabolism. Genes related to the extracellular matrix are known to be important factors for enhancing tumorigenicity and promoting metastasis ([@b29-ijo-48-01-0367]). Although CDKN2A and RB1 are known to function in the same pathway of cell cycle regulation, inactivation of the mutations might have a different functional role in cancer development or progression in SCLC and NSCLC subtypes.

Specific change in total proteins and phosphoproteins in RB1 and CDKN2A mutations
---------------------------------------------------------------------------------

We characterized the differential regulation of *RB1* and *CDKN2A* mutations at the protein level using RPPA data of 77 pan- and 38 phospho-antibodies for 89 proteins across 179 cancer cell lines. Consistent with the patterns of gene expression data, the overall protein expression and phosphorylation status were inversely correlated between RB1*mt* SCLC and CDKN2A*mt* NSCLC cell lines ([Fig. 4](#f4-ijo-48-01-0367){ref-type="fig"}). Thus, the mutational effect of *RB1* and *CDKN2A* genes were separately analyzed in SCLC and NSCLC cell lines ([Fig. 5](#f5-ijo-48-01-0367){ref-type="fig"}). The results showed that β-catenin was commonly over expressed in both *RB1* and *CDKN2A* mutants. Wnt/β-catenin overexpression has been extensively reported in lung cancer ([@b30-ijo-48-01-0367]), and the overexpression of β-catenin might be maintained by the mutational effect of both *RB1* and *CDKN2A* genes. The *RB1* mutation specifically regulated PTEN, STAT, mTOR, p53 expression and MAPK phosphorylation in SCLC cells. However, the *CDKN2A* mutation altered the expression of JNK2 and cKIT and the phosphorylation status of AKT, STAT3 and AMPKa.

MAPK (T202), which is significantly (p\<0.05) phosphorylated in *RB1*-mutated SCLC cancer cell lines, has an important role in transcriptional regulation of targeting transcription factors such as c-Jun, c-Fos, and c-Myc ([@b31-ijo-48-01-0367]). This observation is consistent with the DNA microarray data ([Fig. 3B](#f3-ijo-48-01-0367){ref-type="fig"}) for RB1*mt* SCLC cells, which are enriched in the functional categories of transcription. AKT is specifically phosphorylated (S473, T308) in CDKN2A*mt* NSCLC and related to focal adhesion ([@b32-ijo-48-01-0367]), which is the enriched gene set of CDKN2A*mt* NSCLC from DNA microarray analysis. Furthermore, PTEN, which was overexpressed in RB1*mt* SCLC cells ([Fig. 5A](#f5-ijo-48-01-0367){ref-type="fig"}), is a well-known negative regulator of AKT activation ([@b33-ijo-48-01-0367]), suggesting that AKT-mediated signaling might be exclusively activated by CDKN2A*mt* in NSCLC, not by RB1*mt* in SCLC. Both proteome and transcriptome data analyses demonstrated that exclusive *RB1* and *CDKN2A* mutations in different subtypes of lung cancer included a differential change of gene expression and protein regulation, even though *RB1* and *CDKN2A* are in the same cell cycle-related pathway.

Synthetic lethality of reciprocal regulation of RB1 and CDKN2A expression
-------------------------------------------------------------------------

Through the systematic analysis of transcriptome and proteome data, we found unique mRNA and protein regulation patterns induced by the mutation of either the *RB1* gene or the *CDKN2A* gene ([Fig. 6A](#f6-ijo-48-01-0367){ref-type="fig"}). Furthermore, we investigated the synergistic negative effect on cancer growth by simultaneous functional loss (or knockdown) of these two genes. We performed a viability assay with diverse lung cancer cell lines with the combined knockdown of *RB1* and *CDKN2A* genes using siRNA-mediated gene depletion. As a result, the knockdown of one of these genes decreased the viability of cells harboring a mutation of the other gene ([Fig. 6B](#f6-ijo-48-01-0367){ref-type="fig"}). The viability of *CDKN2A*-mutant cell lines was significantly decreased by knockdown of *RB1*; similarly, *RB1*-mutant cell lines were inhibited by *CDKN2A* depletion. Consistently, the simultaneous depletion of *RB1* and *CDKN2A* genes significantly decreased the viability of lung cell lines harboring wild-types of these genes ([Fig. 6C](#f6-ijo-48-01-0367){ref-type="fig"}). However, the single knockdown of either the *RB1* gene or the *CDKN2A* gene did not effectively reduce viability in these wild-type cell lines. In conclusion, the functional inhibition of the *RB1* or *CDKN2A* gene in CDKN2A*mt* or RB1*mt* cancer cells, respectively, might be a promising therapeutic approach in SCLC or NSCLC lung cancers. The present study on differential proteome and transcriptome profiles between two mutant groups provides mechanistic insights into the synthetic lethality of RB1 and CDKN2A mutations.
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![*RB1* and *CDKN2A* mutation frequency in the cancer cell line panel. (A) Enrichment score of *RB1* and *CDKN2A* mutation frequency among diverse cancer lineages. The enrichment score was calculated by the odds ratio between the observed and expected odds. The observed odds ratio is the ratio for *RB1* or *CDKN2A* mutation among each cancer type. The expected odds ratio is the ratio for *RB1* or *CDKN2A* mutation among all 318 cell lines. (B) The enrichment score of major mutation frequency in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The observed odds ratio is the ratio for each mutation frequency in 46 NSCLC or 25 SCLC cell lines. The expected odds ratio is the ratio for each mutation frequency in all 318 cell lines. (C) The distribution of major gene mutations in lung cancer cell lines. Statistical significance of ^\*^p\<0.05 and ^\*\*^p\<0.01, respectively.](IJO-48-01-0367-g00){#f1-ijo-48-01-0367}

![Comparison of gene expression in SCLC and NSCLC with the mutational status of *RB1* and *CDKN2A*. (A) The expression change of a total of 22,357 gene probes in SCLC and NSCLC cell lines. Major categories of the gene sets significantly (p\<0.01) over-enriched for each gene expression were analyzed using gene set enrichment analysis (GSEA). Gene sets from different pathway DBs (orange, Reactome; sky-blue, PID; purple, KEGG; and green, Biocarta) were collected. The number indicates the number of gene sets per category. (B) Comparison of gene expressional change in *RB1*-mutated SCLC and *CDKN2A*-mutated NSCLC. Red represents 1,208 *RB1*-mutated SCLC-specific gene signatures and blue represents 159 *RB1*-mutated SCLC-specific gene signatures (\>2-fold change and p\<0.01). A total of 42 gene probes were commonly selected between them. (C) Comparison of gene expression change in SCLC and NSCLC cell lines with *RB1* and *CDKN2A* wild-type, respectively. The colored gene signatures were consistent with (B). The expressional change for each gene probe was calculated by the log~2~ fold change via the median across 318 cell lines. The *r* value represents the Pearson correlation coefficient.](IJO-48-01-0367-g01){#f2-ijo-48-01-0367}

![RB1*mt*- and CDKN2A*mt*-specific gene signatures in SCLC and NSCLC cells. (A) Enrichment score (ES) map of significantly (p\<0.01) over-enriched gene sets in SCLC and NSCLC cell lines. Each subtype was further divided by *RB1* or *CDKN2A* mutational status. The color index on the right side represents the functional category of clustered gene sets. The individual gene expression level in [Fig. 2](#f2-ijo-48-01-0367){ref-type="fig"} was used for gene set enrichment analysis (GSEA). (B) Comparison of gene expression change along *RB1* and *CDKN2A* mutations. The red color represents 159 transcription markers specific to the *RB1* mutation, and blue represents 122 transcription markers specific to the *CDKN2A* mutation (\>2-fold change and p\<0.05). The complete list of the selected markers is available in [Table I](#tI-ijo-48-01-0367){ref-type="table"} and [II](#tII-ijo-48-01-0367){ref-type="table"}. The scale of the plot is log~2~ fold change of differential gene expression. It was calculated by the differences of average log~2~ gene expression between mutation and wild-type cell lines in a given subtype. Major categories of the gene sets significantly (p\<0.01) over-enriched for each gene expression were analyzed by GSEA. Gene sets from different pathway DBs (orange, Reactome; sky-blue, PID; purple, KEGG; and green, Biocarta) were collected. The value next to each category indicates the number of sub-gene sets. The *r* value represents the Pearson correlation coefficient.](IJO-48-01-0367-g02){#f3-ijo-48-01-0367}

![Comparison of protein expression and phosphorylation in SCLC and NSCLC with the mutational status of *RB1* and *CDKN2A*. Protein expression change of a total of 77 pan-antibodies was compared between (A) SCLC and NSCLC, (B) *RB1*-mutated SCLC and *CDKN2A*-mutated NSCLC, and (C) SCLC and NSCLC with *RB1* and *CDKN2A* wild-type cell lines, respectively. Protein phosphorylation change of a total of 38 phospho-antibodies was compared between (D) SCLC and NSCLC, (E) *RB1*-mutated SCLC and *CDKN2A*-mutated NSCLC, and (F) SCLC and NSCLC with *RB1* and *CDKN2A* wild-type cell lines, respectively. The phosphorylation change for each protein phospho-antibody was calculated by the log~2~ fold change via the median across 179 cell lines. The *r* value represents the Pearson correlation coefficient.](IJO-48-01-0367-g03){#f4-ijo-48-01-0367}

![Protein and phosphoprotein signatures specific to *RB1* or *CDKN2A* mutations. (A) Comparison of differential protein expression (77 pan-antibody data) between *RB1* and *CDKN2A* mutations. (B) Comparison of differential protein phosphorylation (38 phospho-antibody data) between *RB1* and *CDKN2A* mutations. The red color represents protein markers specific to the *RB1* mutation, and blue represents protein markers specific to the *CDKN2A* mutation (\>1-fold change and p\<0.05). The scale of the plots is the log~2~ fold change of protein expression and phosphorylation, respectively. The value was calculated by the differences of average log~2~ expression or phosphorylation level between mutation and wild-type cell lines in the given subtype. The *r* value represents the Pearson correlation coefficient.](IJO-48-01-0367-g04){#f5-ijo-48-01-0367}

![Differential viability change of lung cancer subtypes induced by reciprocal knockdown of the *RB1* and/or *CDKN2A* genes. (A) A schematic summary of biological functions dysregulated by the mutation status of *RB1* and *CDKN2A*. (B) The effects of siRB1 and siCDKN2A in lung cell lines with *CDKN2A* mutations (NCI-H82 and NCI-H524) and *RB1* mutations (NCI-H460, A549, NCI-H322M, and NCI-H226), respectively. (C) The effect of single- or double-knockdown of *RB1* and *CDKN2A* gene expression on the viability of *RB1*- and *CDKN2A*-positive cell lines (EKVX, NCI-H23, NCI-H1395, and NCI-H1993). The cells were incubated in siRB1 and siCDKN2A and cultured for 72 h. Cell viability was determined using a CellTiter-Blue assay. The siRNA-mediated gene depletion efficacy of *RB1* or *CDKN2A* in each tested cell line was evaluated (data not shown). The % cell viability was calculated using siNC as the negative control for each siRNA treatment. ^\*^p\<0.05 and ^\*\*^p\<0.01 between the compared groups.](IJO-48-01-0367-g05){#f6-ijo-48-01-0367}

###### 

The RB1*mt*-specific gene signatures in SCLC.

  Upregulated genes specific to RB1*mt*   Downregulated genes specific to RB1*mt*                                                              
  --------------------------------------- ----------------------------------------- ------- ------- --------------- ----------------- -------- -------
  231736_x\_at                            MGST1                                     2.083   0.001   202834_at       AGT               −3.059   0
  218847_at                               IGF2BP2                                   2.058   0.011   1566764_at      MACC1             −2.16    0.035
  202620_s\_at                            PLOD2                                     2.01    0.002   205501_at       PDE10A            −2.159   0.004
  213139_at                               SNAI2                                     2.002   0.016   204044_at       QPRT              −2.149   0.004
  206332_s\_at                            IFI16                                     1.879   0.03    239503_at       Unknown           −2.041   0
  235763_at                               SLC44A5                                   1.829   0.009   208891_at       DUSP6             −2.019   0.006
  204646_at                               DPYD                                      1.828   0.005   1560652_at      Unknown           −1.943   0.019
  202016_at                               MEST                                      1.817   0.003   203881_s\_at    DMD               −1.937   0.006
  226225_at                               MCC                                       1.717   0.045   208892_s\_at    DUSP6             −1.921   0.005
  217028_at                               CXCR4                                     1.675   0.023   206218_at       MAGEB2            −1.732   0.013
  214597_at                               SSTR2                                     1.655   0.038   203132_at       RB1               −1.709   0.006
  210839_s\_at                            ENPP2                                     1.557   0.04    205305_at       FGL1              −1.67    0.006
  203038_at                               PTPRK                                     1.531   0.001   201328_at       ETS2              −1.663   0.005
  222553_x\_at                            OXR1                                      1.528   0.003   205110_s\_at    FGF13             −1.651   0.036
  1558217_at                              SLFN13                                    1.515   0.045   209365_s\_at    ECM1              −1.61    0.014
  1565162_s\_at                           MGST1                                     1.493   0.016   210102_at       VWA5A             −1.597   0.005
  204620_s\_at                            VCAN                                      1.47    0.011   209468_at       LRP5              −1.583   0.001
  221731_x\_at                            VCAN                                      1.44    0.018   1558882_at      LOC401233         −1.574   0.032
  218197_s\_at                            OXR1                                      1.409   0.006   219750_at       TMEM144           −1.572   0.034
  205229_s\_at                            COCH                                      1.338   0.006   223748_at       SLC4A11           −1.552   0.002
  203184_at                               FBN2                                      1.338   0.026   205601_s\_at    HOXB5             −1.511   0.023
  205027_s\_at                            MAP3K8                                    1.311   0.004   209803_s\_at    PHLDA2            −1.495   0.038
  204030_s\_at                            SCHIP1                                    1.308   0.038   212268_at       SERPINB1          −1.467   0.001
  241400_at                               Unknown                                   1.296   0.006   1569191_at      ZNF826            −1.448   0.022
  1555788_a\_at                           TRIB3                                     1.274   0.034   212188_at       KCTD12            −1.43    0.002
  211675_s\_at                            MDFIC                                     1.272   0.012   241672_at       C13orf36          −1.414   0.033
  229465_s\_at                            PTPRS                                     1.255   0.008   219305_x\_at    FBXO2             −1.337   0.015
  225093_at                               UTRN                                      1.255   0.042   1554472_a\_at   PHF20L1           −1.317   0
  205122_at                               TMEFF1                                    1.251   0.01    203028_s\_at    CYBA              −1.308   0.047
  219489_s\_at                            NXN                                       1.238   0.035   228726_at       Unknown           −1.303   0.01
  225056_at                               SIPA1L2                                   1.237   0.011   204158_s\_at    TCIRG1            −1.302   0.006
  208949_s\_at                            LGALS3                                    1.235   0.021   211538_s\_at    HSPA2             −1.279   0.035
  201063_at                               RCN1                                      1.229   0.033   220082_at       PPP1R14D          −1.259   0.008
  235244_at                               CCDC58                                    1.184   0.032   203005_at       LTBR              −1.257   0.011
  210978_s\_at                            TAGLN2                                    1.184   0.005   229964_at       C9orf152          −1.23    0.036
  233903_s\_at                            SGEF                                      1.182   0.003   203961_at       NEBL              −1.212   0.032
  205123_s\_at                            TMEFF1                                    1.177   0.019   224577_at       ERGIC1            −1.206   0.002
  200897_s\_at                            PALLD                                     1.164   0.018   238021_s\_at    CRNDE             −1.189   0.022
  200916_at                               TAGLN2                                    1.161   0.015   223041_at       CD99L2            −1.182   0.001
  215127_s\_at                            RBMS1                                     1.143   0.03    205586_x\_at    VGF               −1.182   0.008
  202887_s\_at                            DDIT4                                     1.141   0.005   239278_at       Unknown           −1.163   0.013
  212636_at                               QKI                                       1.137   0.014   213689_x\_at    FAM69A            −1.157   0.005
  214877_at                               CDKAL1                                    1.134   0.03    232099_at       PCDHB16           −1.153   0.028
  227197_at                               SGEF                                      1.129   0.005   219256_s\_at    SH3TC1            −1.153   0.005
  224918_x\_at                            MGST1                                     1.12    0.02    227943_at       Unknown           −1.141   0.004
  227522_at                               CMBL                                      1.08    0.007   210538_s\_at    BIRC3             −1.138   0.024
  206385_s\_at                            ANK3                                      1.073   0.042   1568838_at      LOC100132169      −1.117   0.032
  226464_at                               C3orf58                                   1.072   0.01    229872_s\_at    LOC100132999      −1.099   0.021
  1568720_at                              ZNF506                                    1.054   0.04    1555579_s\_at   PTPRM             −1.09    0.043
  201656_at                               ITGA6                                     1.04    0.028   224997_x\_at    H19               −1.082   0.032
  212190_at                               SERPINE2                                  1.034   0.037   213005_s\_at    KANK1             −1.081   0.01
  204995_at                               CDK5R1                                    1.022   0.017   219371_s\_at    KLF2              −1.076   0.013
  210512_s\_at                            VEGFA                                     1.02    0.037   37408_at        MRC2              −1.074   0.01
  226419_s\_at                            FLJ44342                                  1.015   0.001   224391_s\_at    SIAE              −1.059   0.01
  210735_s\_at                            CA12                                      1.011   0.032   201329_s\_at    ETS2              −1.053   0.022
  65588_at                                LOC388796                                 1.002   0.009   205016_at       TGFA              −1.049   0.007
  213857_s\_at                            CD47                                      1.001   0.002   227384_s\_at    LOC727820         −1.043   0.002
  208622_s\_at                            EZR                                       1.001   0.001   228010_at       PPP2R2C           −1.033   0.031
                                                                                                    209500_x\_at    TNFSF12/TNFSF13   −1.031   0.019
                                                                                                    224576_at       ERGIC1            −1.031   0.007
                                                                                                    236719_at       Unknown           −1.025   0.004
                                                                                                    227001_at       NIPAL2            −1.021   0.006
                                                                                                    230722_at       BNC2              −1.019   0.047
                                                                                                    204682_at       LTBP2             −1.007   0.024

###### 

The CDKN2A*mt*-specific gene signatures in NSCLC.

  Upregulated genes specific to CDKN2A*mt*   Downregulated genes specific to CDKN2A*mt*                                                                              
  ------------------------------------------ -------------------------------------------- ------- ------- --------------- --------------------------------- -------- -------
  236694_at                                  CYorf15A                                     2.585   0.001   228956_at       UGT8                              −1.618   0.001
  211980_at                                  COL4A1                                       1.978   0.006   209644_x\_at    CDKN2A                            −1.52    0.004
  213725_x\_at                               XYLT1                                        1.654   0.023   225681_at       CTHRC1                            −1.396   0.014
  204971_at                                  CSTA                                         1.615   0.022   1554242_a\_at   COCH                              −1.373   0.008
  209970_x\_at                               CASP1                                        1.566   0.001   218820_at       C14orf132                         −1.199   0.012
  225688_s\_at                               PHLDB2                                       1.412   0.017   200884_at       CKB                               −1.191   0.001
  202638_s\_at                               ICAM1                                        1.388   0.011   227623_at       Unknown                           −1.156   0.018
  222453_at                                  CYBRD1                                       1.377   0.016   207558_s\_at    PITX2                             −1.151   0.014
  1562102_at                                 AKR1C1                                       1.344   0.048   236302_at       PPM1E                             −1.151   0.009
  208782_at                                  FSTL1                                        1.312   0.014   209198_s\_at    SYT11                             −1.145   0.007
  211340_s\_at                               MCAM                                         1.299   0.002   1560023_x\_at   Unknown                           −1.097   0.01
  210004_at                                  OLR1                                         1.299   0.01    214321_at       NOV                               −1.094   0.035
  202008_s\_at                               NID1                                         1.286   0.004   205229_s\_at    COCH                              −1.061   0.031
  202350_s\_at                               MATN2                                        1.197   0.012   223551_at       PKIB                              −1.045   0.046
  239999_at                                  Unknown                                      1.126   0.033   230130_at       Unknown                           −1.04    0.049
  205407_at                                  RECK                                         1.117   0.014   212706_at       LOC100286937/LOC100287164/RASA4   −1.019   0.003
  203304_at                                  BAMBI                                        1.113   0.012                                                              
  228698_at                                  SOX7                                         1.104   0.014                                                              
  227051_at                                  Unknown                                      1.088   0.036                                                              
  201939_at                                  PLK2                                         1.082   0.017                                                              
  209087_x\_at                               MCAM                                         1.081   0.007                                                              
  206165_s\_at                               CLCA2                                        1.067   0.025                                                              
  227178_at                                  CUGBP2                                       1.067   0.012                                                              
  227253_at                                  CP                                           1.044   0.015                                                              
  212262_at                                  QKI                                          1.043   0.002                                                              
  202998_s\_at                               LOXL2                                        1.039   0.006                                                              
  214022_s\_at                               IFITM1                                       1.021   0.034                                                              
  211366_x\_at                               CASP1                                        1.019   0.001                                                              
  222446_s\_at                               BACE2                                        1.014   0.009                                                              
